Chinese Biotech Company Claims Its Pill Could Help Humans Live to 150

Humans have spent centuries chasing the same impossible-sounding prize: more time. Now, a Chinese biotech company claims it may have found a way to push the limits of human lifespan, with a pill that it says could eventually help people live as long as 150 years.

The capsule is being developed by Shenzhen-based Lonvi Biosciences, and its headline ingredient comes from an unexpectedly familiar source: grape seeds. The company says its treatment targets aging cells that linger inside the body, and its claims have already sparked huge questions about whether extreme longevity could one day move from science fiction into medicine.

The Company Says 150 Could Be Realistic

Lonvi Biosciences is developing a capsule built around procyanidin C1, or PCC1, a compound derived from grape seeds. The company is targeting cells associated with aging and believes removing or controlling these damaged cells could help slow some of the biological processes linked to getting older.

These aging cells are sometimes called “zombie cells” because they stop behaving like healthy cells but can remain inside the body. Rather than simply disappearing, they can continue producing signals that affect surrounding tissue and contribute to inflammation and other age-related problems.

Lonvi CEO Ip Zhu has made an unusually bold prediction about where the research could lead. “This is not just another pill. This is the Holy Grail,” Zhu said while describing the company’s ambitions for extreme longevity.

The company believes its approach could eventually do more than simply add years to someone’s life. Lonvi says PCC1 may help maintain cellular health, slow deterioration and preserve energy production as people age, potentially delaying some diseases associated with getting older.

The Ingredient Has Already Been Tested In Mice

PCC1 has attracted interest because research has found that the compound can affect aging-related processes in laboratory animals. Lonvi has also conducted its own mouse experiments and reported results that sound striking when translated into lifespan percentages.

According to the company’s reported results, treatment increased overall lifespan by 9.4%. Lonvi also reported that mice receiving the treatment from the first day of the experiment experienced a 64% extension in lifespan.

Those figures are the part of the story most likely to grab attention, but they need to be put into context. The reported results involve mice, and there is currently no evidence in the supplied material showing that humans would experience anything close to the same lifespan extension.

That distinction becomes particularly important when the proposed goal is 150 years. Animal studies can reveal biological mechanisms worth investigating, but they cannot establish that a treatment will safely extend human life by several decades.

“Zombie Cells” Are The Target

The basic idea behind the treatment comes from research into cellular senescence. As organisms age, some cells become damaged or dysfunctional and enter a state where they stop dividing but do not necessarily leave the body.

Those cells can release substances that affect nearby cells and tissues. Researchers have been studying whether targeting senescent cells could reduce some of the problems associated with aging and improve health during later life.

Lonvi believes PCC1 could be useful because of its effects on these aging cells. The company says the compound can help strengthen cells, limit deterioration and support the body’s ability to maintain energy production over time.

That does not mean the pill has been proven to stop aging. It means the company is pursuing one biological pathway that researchers are already interested in, then attempting to turn that science into a treatment capable of producing meaningful effects in humans.

The 150-Year Prediction Goes Even Further

Lonvi’s Chief Technology Officer Lyu Qinghua has been even more confident about the company’s long-term prospects. “Living to 150 is definitely realistic,” Qinghua said, adding that he believes it could become reality within a few years.

That timeline is far more ambitious than the evidence currently described. A treatment moving from promising laboratory findings to an established human medicine typically has to clear multiple stages of testing, with researchers examining effectiveness, side effects and long-term safety.

Longevity also creates a problem that many ordinary medicines do not face. If the goal is to extend someone’s life for decades, researchers need to understand what happens after prolonged exposure and whether delaying one age-related problem creates another.

For that reason, the biggest question surrounding Lonvi’s capsule is not whether mice lived longer. It is whether the same biological mechanism can produce a meaningful and safe effect in people.

China Is Building A Longevity Industry

The company’s ambitions are arriving as interest in longevity research grows rapidly across China. Aging research has increasingly become part of the country’s broader biotechnology push, with longevity projects attracting attention from entrepreneurs, researchers and investors.

That represents a major shift from the way the subject was viewed in previous years. Gan Yu, co-founder of Shanghai-based longevity startup Time Pie, described the changing attitude toward life extension by saying, “Nobody in China used to talk about longevity, only rich Americans.”

Yu added that interest has changed as more people have both the desire and financial resources to pursue longer lives. The growing industry reflects a wider global fascination with finding ways to delay the effects of aging.

There is also a significant difference between wanting to live longer and wanting to remain healthy for longer. A successful longevity treatment would ideally delay disease and preserve physical function rather than simply keep the body alive for additional years.

That distinction could eventually become more important than the 150-year headline. If researchers can safely delay several diseases associated with aging, even a much smaller increase in healthy lifespan could have enormous consequences.

The Price Claim Needs A Reality Check

The viral post surrounding the story suggests that the price of the pill is surprising. However, the supplied reference material does not provide a verified retail price for a commercially available Lonvi PCC1 capsule.

That means claims about a specific monthly cost should not be treated as established fact based on the material currently available. The company is discussing an experimental longevity treatment, and the supplied information does not establish that a finished consumer product is already sitting on pharmacy shelves.

This is an important detail because viral longevity stories can quickly blur the line between a company’s research program and a finished medicine. A promising compound in development is very different from a treatment that has completed human testing and received approval for widespread use.

For now, the more reliable story is the science behind PCC1 and the extraordinary ambition attached to it. The 150-year figure remains a prediction from the company rather than a demonstrated medical outcome.

Living To 150 Would Change Almost Everything

Even if researchers eventually develop treatments that extend healthy lifespan, reaching 150 would create questions far beyond medicine. Careers, retirement, family structures and the way people think about different stages of life could all change dramatically if humans regularly remained healthy for much longer.

There would also be a major question of access. If extreme longevity treatments were expensive, the ability to live substantially longer could initially become concentrated among people who could afford them, creating an entirely new form of inequality.

Longevity research therefore involves more than finding a molecule that works in a laboratory. Scientists would need to establish that treatments are safe, effective and capable of improving health rather than simply extending the period in which people experience age-related decline.

The most useful breakthrough may eventually have little to do with the number 150. If medicine can keep people healthier for longer, prevent age-related diseases and preserve independence into old age, the impact could be enormous even without anyone approaching that extreme lifespan.

The Biggest Test Has Not Happened Yet

Lonvi’s PCC1 research is intriguing because it focuses on a biological process that scientists are actively studying. Its reported mouse results give the company a basis for continuing that work, but they do not prove that the same effect exists in humans.

Before a 150-year lifespan becomes anything more than a bold prediction, the treatment will need evidence from human testing. Researchers will have to determine whether PCC1 works in people, how safe it is over long periods and whether it actually delays the diseases associated with aging.

For now, the pill remains an experimental idea with an extraordinary promise attached to it. The mice may have offered Lonvi a reason to keep going, but humans will decide whether the 150-year dream has any real chance of surviving.